Janus Henderson Group PLC Sells 32,182 Shares of Immunome, Inc. (NASDAQ:IMNM)

Janus Henderson Group PLC lessened its holdings in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 0.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,455,939 shares of the company's stock after selling 32,182 shares during the period. Janus Henderson Group PLC owned 4.33% of Immunome worth $36,726,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of IMNM. BNP Paribas Financial Markets acquired a new position in shares of Immunome in the 4th quarter valued at $70,000. KLP Kapitalforvaltning AS purchased a new position in shares of Immunome in the 4th quarter worth $75,000. AlphaQuest LLC boosted its holdings in Immunome by 786,700.0% in the fourth quarter. AlphaQuest LLC now owns 7,868 shares of the company's stock valued at $84,000 after acquiring an additional 7,867 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Immunome by 482.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,608 shares of the company's stock valued at $91,000 after acquiring an additional 7,129 shares during the last quarter. Finally, Aquatic Capital Management LLC purchased a new stake in Immunome during the fourth quarter valued at about $95,000. Hedge funds and other institutional investors own 44.58% of the company's stock.

Insider Transactions at Immunome

In related news, CEO Clay B. Siegall bought 137,100 shares of the business's stock in a transaction on Wednesday, March 26th. The shares were bought at an average cost of $7.29 per share, for a total transaction of $999,459.00. Following the completion of the acquisition, the chief executive officer now directly owns 806,736 shares in the company, valued at approximately $5,881,105.44. This represents a 20.47% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CTO Philip Tsai purchased 12,300 shares of the firm's stock in a transaction on Monday, March 24th. The shares were purchased at an average price of $8.42 per share, with a total value of $103,566.00. Following the completion of the acquisition, the chief technology officer now directly owns 33,300 shares of the company's stock, valued at approximately $280,386. This trade represents a 58.57% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 156,400 shares of company stock valued at $1,160,495. 8.60% of the stock is owned by insiders.

Immunome Trading Up 4.6%

NASDAQ:IMNM traded up $0.37 during mid-day trading on Tuesday, reaching $8.38. 161,512 shares of the stock were exchanged, compared to its average volume of 917,020. The business has a fifty day moving average price of $7.62 and a 200 day moving average price of $9.77. Immunome, Inc. has a 1-year low of $5.15 and a 1-year high of $16.81. The firm has a market capitalization of $729.07 million, a PE ratio of -1.03 and a beta of 2.00.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.14. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%. The firm had revenue of $2.93 million for the quarter, compared to the consensus estimate of $0.46 million. On average, sell-side analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Lifesci Capital assumed coverage on Immunome in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $20.00 price objective on the stock. Lake Street Capital began coverage on shares of Immunome in a research report on Wednesday, April 2nd. They set a "buy" rating and a $23.00 price target on the stock. Wedbush reissued an "outperform" rating and issued a $21.00 target price (down previously from $33.00) on shares of Immunome in a research note on Tuesday, May 13th. Guggenheim lowered their price target on Immunome from $35.00 to $25.00 and set a "buy" rating for the company in a report on Thursday, March 20th. Finally, Stephens restated an "overweight" rating and set a $30.00 price objective on shares of Immunome in a research note on Thursday, March 20th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $23.33.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.